SCHEMBL1751456

SCHEMBL1751456

C=C(F)[Sn](CCCC)(CCCC)CCCC

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203812 0.78 TSHR (0.33) ALDH1A1LMNATSHR
SCHEMBL6711637 0.78 TSHR (0.33) ALDH1A1LMNATSHR
SCHEMBL437089 0.78 TSHR (0.33) ALDH1A1LMNATSHR
SCHEMBL1899483 0.74 ALDH1A1 (0.30) ALDH1A1LMNATSHR
SCHEMBL7792024 0.74 ALDH1A1 (0.30) ALDH1A1LMNATSHR
SCHEMBL808949 0.73 FAAH (0.35)
SCHEMBL4333058 0.72 ALDH1A1 (0.31) ALDH1A1TSHR
SCHEMBL8799521 0.72
SCHEMBL28831186 0.72
SCHEMBL28831243 0.72 CES1 (0.36) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2023-01-12 US disclosed
US-11034668-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2021-06-15 US disclosed
US-10370358-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2019-08-06 US disclosed
US-20180194746-A1 Compounds For the Treatment of HIV GILEAD SCIENCES, INC. 2018-07-12 US disclosed
US-9944619-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2018-04-17 US disclosed
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2017-05-18 US disclosed
US-9603364-B2 4-amino-6-(halo-substituted-alkyl)-picolinates and their use as herbicides DOW AGROSCIENCES LLC (US) 2017-03-28 US disclosed
US-9540343-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2017-01-10 US disclosed
EP-3080083-A1 4-AMINO-6-(HALO-SUBSTITUTED-ALKYL)-PICOLINATES AND THEIR USE AS HERBICIDES Dow AgroSciences LLC (US) 2016-10-19 EP disclosed
EP-2193120-B1 2-SUBSTITUTED-6-AMINO-5-ALKYL, ALKENYL OR ALKYNYL-4-PYRIMIDINECARBOXYLIC ACIDS AND 6-SUBSTITUTED-4-AMINO-3- ALKYL, ALKENYL OR ALKYNYL PICOLINIC ACIDS AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC (US) 2016-07-13 EP disclosed
US-20050148649-A1 Substituted arylpyrazoles ZOETIS SERVICES LLC 2005-07-07 US disclosed
WO-2005060749-A1 SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS PFIZER LIMITED (GB) 2005-07-07 WO disclosed
EP-0745071-A1 4-AMINO 6-SUBSTITUTED MYCOPHENOLIC ACID AND DERIVATIVES WITH IMMUNOSUPPRESSIVE ACTIVITY SYNTEX (U.S.A.) INC. (US) 1996-12-04 EP disclosed
EP-0745075-A1 6-SUBSTITUTED MYCOPHENOLIC AND DERIVATIVES WITH IMMUNOSUPPRESSIVE ACTIVITY SYNTEX (U.S.A.) INC. (US) 1996-12-04 EP disclosed
US-5554612-A IMMUNOSUPPRESSANTS, VIRICIDES, ANTITUMOR AND ANTIINFLAMMATORY AGENTS SYNTEX INC (US) 1996-09-10 US disclosed
US-5536747-A ENZYME INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-07-16 US disclosed
US-5525602-A TREATING INFLAMMATORY DISEASES, PREVENTING ALLOGRAFT REJECTION, AUTOIMMUNE DISEASES SYNTEX (U.S.A.) INC. (US) 1996-06-11 US disclosed
WO-1995022534-A1 4-AMINO 6-SUBSTITUTED MYCOPHENOLIC ACID AND DERIVATIVES WITH IMMUNOSUPPRESSIVE ACTIVITY SYNTEX (U.S.A.) INC. (US) 1995-08-24 WO disclosed
WO-1995022536-A1 6-SUBSTITUTED MYCOPHENOLIC AND DERIVATIVES WITH IMMUNOSUPPRESSIVE ACTIVITY SYNTEX (U.S.A.) INC. (US) 1995-08-24 WO disclosed
US-5444072-A Useful in treatment of autoimmune disorders, psoriasis, inflammatory diseases, rheumatoid arthritis SYNTEX (U.S.A.) INC. (US) 1995-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370358-B2 Compounds for the treatment of HIV CCR5, NPC1, FURIN ALDH1A1 649/4885LMNA 3182/4885TSHR 4824/4885
US-20180194746-A1 Compounds For the Treatment of HIV CCR5, NPC1, FURIN ALDH1A1 649/4885LMNA 3182/4885TSHR 4824/4885
US-20050148649-A1 Substituted arylpyrazoles CYP3A4, CYP4B1, CYP1B1 ALDH1A1 346/4885LMNA 4311/4885TSHR 1886/4885
US-11034668-B2 Compounds for the treatment of HIV CCR5, NPC1, FURIN ALDH1A1 649/4885LMNA 3182/4885TSHR 4824/4885
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN ALDH1A1 649/4885LMNA 3182/4885TSHR 4824/4885
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN ALDH1A1 649/4885LMNA 3182/4885TSHR 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.